251 related articles for article (PubMed ID: 15371906)
1. Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population.
Kornreich R; Ekstein J; Edelmann L; Desnick RJ
Genet Med; 2004; 6(5):415-20. PubMed ID: 15371906
[TBL] [Abstract][Full Text] [Related]
2. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population.
Abeliovich D; Lavon IP; Lerer I; Cohen T; Springer C; Avital A; Cutting GR
Am J Hum Genet; 1992 Nov; 51(5):951-6. PubMed ID: 1384328
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of cystic fibrosis mutations in Israeli Jews.
Orgad S; Neumann S; Loewenthal R; Netanelov-Shapira I; Gazit E
Genet Test; 2001; 5(1):47-52. PubMed ID: 11336401
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis in Jews: frequency and mutation distribution.
Kerem B; Chiba-Falek O; Kerem E
Genet Test; 1997; 1(1):35-9. PubMed ID: 10464623
[TBL] [Abstract][Full Text] [Related]
5. The D1152H cystic fibrosis mutation in prenatal carrier screening, patients and prenatal diagnosis.
Peleg L; Karpati M; Bronstein S; Berkenstadt M; Frydman M; Yonath H; Pras E
J Med Screen; 2011; 18(4):169-72. PubMed ID: 22156145
[TBL] [Abstract][Full Text] [Related]
6. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening.
Quint A; Lerer I; Sagi M; Abeliovich D
Am J Med Genet A; 2005 Jul; 136(3):246-8. PubMed ID: 15948195
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis heterozygote screening in the Orthodox Community of Ashkenazi Jews: the Dor Yesharim approach and heterozygote frequency.
Abeliovich D; Quint A; Weinberg N; Verchezon G; Lerer I; Ekstein J; Rubinstein E
Eur J Hum Genet; 1996; 4(6):338-41. PubMed ID: 9043867
[TBL] [Abstract][Full Text] [Related]
8. Difference in frequencies of the cystic fibrosis alleles, delta F508 and W1282X, between carriers and patients.
Kalman YM; Kerem E; Darvasi A; DeMarchi J; Kerem B
Eur J Hum Genet; 1994; 2(2):77-82. PubMed ID: 8044659
[TBL] [Abstract][Full Text] [Related]
9. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.
Scott SA; Edelmann L; Liu L; Luo M; Desnick RJ; Kornreich R
Hum Mutat; 2010 Nov; 31(11):1240-50. PubMed ID: 20672374
[TBL] [Abstract][Full Text] [Related]
10. Preconception and prenatal cystic fibrosis carrier screening of African Americans reveals unanticipated frequencies for specific mutations.
Monaghan KG; Bluhm D; Phillips M; Feldman GL
Genet Med; 2004; 6(3):141-4. PubMed ID: 15354332
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis mutations with widely variable phenotype: the D1152H example.
Mussaffi H; Prais D; Mei-Zahav M; Blau H
Pediatr Pulmonol; 2006 Mar; 41(3):250-4. PubMed ID: 16429425
[TBL] [Abstract][Full Text] [Related]
12. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
Kronn D; Jansen V; Ostrer H
Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
[TBL] [Abstract][Full Text] [Related]
13. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.
Shoshani T; Augarten A; Gazit E; Bashan N; Yahav Y; Rivlin Y; Tal A; Seret H; Yaar L; Kerem E
Am J Hum Genet; 1992 Jan; 50(1):222-8. PubMed ID: 1370365
[TBL] [Abstract][Full Text] [Related]
14. The Ashkenazi Jewish carrier screening panel: evolution, status quo, and disparities.
Hoffman JD; Park JJ; Schreiber-Agus N; Kornreich R; Tanner AK; Keiles S; Friedman KJ; Heim RA
Prenat Diagn; 2014 Dec; 34(12):1161-7. PubMed ID: 24996053
[TBL] [Abstract][Full Text] [Related]
15. Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis.
Sereth H; Shoshani T; Bashan N; Kerem BS
Hum Genet; 1993 Oct; 92(3):289-95. PubMed ID: 7691712
[TBL] [Abstract][Full Text] [Related]
16. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.
Sugarman EA; Rohlfs EM; Silverman LM; Allitto BA
Genet Med; 2004; 6(5):392-9. PubMed ID: 15371903
[TBL] [Abstract][Full Text] [Related]
17. CFTR DeltaF508 mutation detection from dried blood samples in the first trimester of pregnancy: a possible routine prenatal screening strategy for cystic fibrosis?
Konialis CP; Hagnefelt B; Kazamia C; Karapanou S; Pangalos C
Fetal Diagn Ther; 2007; 22(1):41-4. PubMed ID: 17003555
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants.
Shi L; Webb BD; Birch AH; Elkhoury L; McCarthy J; Cai X; Oishi K; Mehta L; Diaz GA; Edelmann L; Kornreich R
Clin Genet; 2017 Apr; 91(4):599-604. PubMed ID: 27415407
[TBL] [Abstract][Full Text] [Related]
19. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis screening: lessons learned from the first 320,000 patients.
Strom CM; Crossley B; Redman JB; Buller A; Quan F; Peng M; McGinnis M; Sun W
Genet Med; 2004; 6(3):136-40. PubMed ID: 15354331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
